Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.-MedSci.cn

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.

Steuer, CE; Hayashi, H; Su, WC; Nishio, M; Johnson, ML; Kim, DW; Koczywas, M; Felip, E; Gold, KA; Murakami, H; Baik, CS; Kim, SW; Smit, EF; Gigantone, M; Kim, B; Fan, PD; Qi, ZH; Wu, EY; Sternberg, DW; Janne, PA

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务